摘要
心脏收缩力调节器(CCM)作为救治慢性射血分数降低的心力衰竭(HFrEF)的新型植入性电子治疗装置,因可增强心室肌收缩力、改善患者症状体征和心功能指标甚至远期预后,已迅速成为心血管领域倍受关注的热点。本文综述了CCM治疗HFrEF的机制和临床研究,并根据其机制和信号传递算法对其在射血分数保留的心力衰竭(HFpEF)、心脏再同步化治疗(CRT)反应不佳、合并心房颤动的HFrEF患者中的疗效进一步分析和展望,以期推动CCM可以满足更多、不同临床情况的心力衰竭患者的需求。
Cardiac contractility modulation(CCM),as a new implantable electronic therapy device for treating chronic heart failure with reduced ejection fraction(HFrEF),has rapidly become a hot topic in the cardiovascular field due to its ability to enhance ventricular myocardial contractility,improve patients’symptoms and signs,cardiac function indexes and even long-term prognosis.This article reviews the mechanism and clinical studies of CCM in treating HFrEF,and based on its mechanism and signal transduction algorithm,further analyzes and prospects its efficacy in patients with heart failure with preserved ejection fraction,cardiac resynchronization therapy non-response,and HFrEF with concomitant atrial fibrillation,aiming to promote CCM to meet the needs of more diverse clinical situations in heart failure patients.
作者
卢群
梁潇
白玲
朱丹军
薛小临
韩克
LU Qun;LIANG Xiao;BAI Ling;ZHU Dan-jun;XUE Xiao-lin;HAN Ke(Department of Cardiology,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
出处
《中国介入心脏病学杂志》
CSCD
2024年第8期457-462,共6页
Chinese Journal of Interventional Cardiology
基金
陕西省科技惠民计划项目(2016HM-04)
陕西省重点研发项目(2020GXLH-Y-015)
国家自然科学基金项目(8210021403)。
关键词
心脏收缩力调节器
射血分数降低的心力衰竭
机制研究
临床研究
Cardiac contractility modulation
Heart failure with reduced ejection fraction
Mechanism studies
Clinical research
